Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2026
Impact of Prior Antithrombotic Therapy on Safety and Outcomes of Endovascular Therapy in Large-Core Acute Ischemic Stroke.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ikenouchi Hajime, Kawabata Yuichi, Saito Takuya, Sakai Nobuyuki, Yamagami Hiroshi, Uchida Kazutaka, Toyoda Kazunori, Matsumaru Yuji, Matsumoto Yasushi, Kimura Kazumi, Ishikura Reiichi, Inoue Manabu, Sakakibara Fumihiro, Morimoto Takeshi, Yoshimura Shinichi, Yazawa Yukako
Аннотация
BACKGROUND AND PURPOSE: Evidence on whether prior antithrombotic drug (ATD) use affects outcomes after endovascular therapy (EVT) is limited in patients with large-core acute ischemic stroke.
MATERIALS AND METHODS: This was a subanalysis of the Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism-Japan Large Ischemic Core Trial, which assessed the efficacy of EVT in patients with large-vessel occlusion and extensive early ischemic changes. The primary outcome was a modified Rankin Scale (mRS) score of 0-3 at 90 days. Secondary outcomes included intracerebral hemorrhage (ICH) within 48 hours, symptomatic ICH, 90-day mortality, ordinal mRS shift, and ≥8-point improvement in National Institutes of Health Stroke Scale score at 48 hours. Logistic regression models were used to assess treatment effects and interactions between ATD and EVT.
RESULTS: A total of 202 patients were included (ATD, n=70; no ATD, n=132). There was no significant interaction between use of ATD and the effect of EVT in terms of the primary outcome (pinteraction=0.944) or secondary outcomes (pinteraction=0.218-0.752). In the EVT cohort, prior ATD use was not associated with the primary outcome (adjusted OR 1.16, 95% CI 0.41-3.23). Results were consistent for antiplatelet drugs (adjusted OR 0.70, 95% CI 0.18-2.71) and anticoagulants (adjusted OR 1.52, 95% CI 0.45-5.20).
CONCLUSIONS: In this exploratory subanalysis, prior ATD use did not significantly modify the observed treatment effect of EVT in patients with large-core acute ischemic stroke. These findings suggest that prior ATD use alone should not preclude consideration of EVT.
MATERIALS AND METHODS: This was a subanalysis of the Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism-Japan Large Ischemic Core Trial, which assessed the efficacy of EVT in patients with large-vessel occlusion and extensive early ischemic changes. The primary outcome was a modified Rankin Scale (mRS) score of 0-3 at 90 days. Secondary outcomes included intracerebral hemorrhage (ICH) within 48 hours, symptomatic ICH, 90-day mortality, ordinal mRS shift, and ≥8-point improvement in National Institutes of Health Stroke Scale score at 48 hours. Logistic regression models were used to assess treatment effects and interactions between ATD and EVT.
RESULTS: A total of 202 patients were included (ATD, n=70; no ATD, n=132). There was no significant interaction between use of ATD and the effect of EVT in terms of the primary outcome (pinteraction=0.944) or secondary outcomes (pinteraction=0.218-0.752). In the EVT cohort, prior ATD use was not associated with the primary outcome (adjusted OR 1.16, 95% CI 0.41-3.23). Results were consistent for antiplatelet drugs (adjusted OR 0.70, 95% CI 0.18-2.71) and anticoagulants (adjusted OR 1.52, 95% CI 0.45-5.20).
CONCLUSIONS: In this exploratory subanalysis, prior ATD use did not significantly modify the observed treatment effect of EVT in patients with large-core acute ischemic stroke. These findings suggest that prior ATD use alone should not preclude consideration of EVT.